Small Gains, Big Wins: How Incremental Yield Increases Drive Major Cost-Savings in Cell and Gene Therapy Manufacturing

Did you know that incremental viral vector yield improvements can lead to significant long-term savings? Virica uses bioprocess modelling to break down key cost drivers of AAV and LV manufacturing and commercial savings unlocked by incorporating enhancer technologies such as our Viral Sensitizers (VSEᵀᴹ). Check out our latest read on how Virica leverages BioSolve bioprocess modelling to enable informed decision-making to drive down manufacturing costs of life-saving therapies.